Villere ST Denis J & Co. LLC Has $8.27 Million Position in Johnson & Johnson (JNJ)

Villere ST Denis J & Co. LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 6.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,574 shares of the company’s stock after purchasing an additional 3,724 shares during the period. Villere ST Denis J & Co. LLC’s holdings in Johnson & Johnson were worth $8,265,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in JNJ. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares during the last quarter. Landmark Financial Advisors LLC raised its position in Johnson & Johnson by 0.4% in the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after buying an additional 7 shares during the last quarter. Paradigm Financial Advisors LLC raised its position in Johnson & Johnson by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock worth $350,000 after buying an additional 9 shares during the last quarter. Premier Asset Management LLC raised its position in Johnson & Johnson by 0.4% in the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after buying an additional 12 shares during the last quarter. Finally, Lbmc Investment Advisors LLC raised its position in Johnson & Johnson by 0.4% in the 2nd quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after buying an additional 14 shares during the last quarter. Institutional investors own 65.71% of the company’s stock.

JNJ has been the subject of a number of recent analyst reports. Citigroup initiated coverage on Johnson & Johnson in a research report on Monday, September 25th. They issued a “neutral” rating and a $140.00 target price for the company. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. UBS Group reissued a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a research report on Saturday, September 30th. Piper Jaffray Companies reissued a “hold” rating and issued a $120.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Finally, Cowen set a $147.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, October 6th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $145.94.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $147.36 on Friday. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $148.32. The company has a market cap of $395,885.59, a PE ratio of 20.64, a PEG ratio of 2.76 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.28%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is currently 58.33%.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/21/villere-st-denis-j-co-llc-has-8-27-million-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply